Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SNCA | P37840 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 6/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8086728 | 0.95 | HIF1A (0.52) | HIF1AALDH1A1TSHRCYP1A2CYP2D6 | |
| Bromide SCHEMBL161462 | 0.95 | HIF1A (0.52) | HIF1AALDH1A1TSHRCYP1A2CYP2D6 | |
| SCHEMBL8376846 | 0.89 | HIF1A (0.46) | HIF1AALDH1A1TSHRCYP1A2CYP2D6 | |
| SCHEMBL8378542 | 0.89 | HIF1A (0.46) | HIF1AALDH1A1TSHRCYP1A2CYP2D6 | |
| SCHEMBL8606124 | 0.89 | HIF1A (0.46) | HIF1AALDH1A1TSHRCYP1A2CYP2D6 | |
| SCHEMBL8374701 | 0.89 | HIF1A (0.46) | HIF1AALDH1A1TSHRCYP1A2CYP2D6 | |
| Iodide SCHEMBL9482438 | 0.81 | HIF1A (0.48) | HIF1AALDH1A1TSHRCYP1A2CYP2D6 | |
| Iodide SCHEMBL9482433 | 0.81 | HIF1A (0.48) | HIF1AALDH1A1TSHRCYP1A2CYP2D6 | |
| Iodide SCHEMBL41863 | 0.79 | HIF1A (0.57) | HIF1AALDH1A1TSHRCYP1A2CYP2D6 | |
| Iodide SCHEMBL30173683 | 0.79 | HIF1A (0.57) | HIF1AALDH1A1TSHRCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018002897-A1 | HYODEOXYCHOLIC ACID DERIVATIVES AND USE THEREOF | BAR PHARMACEUTICALS SOCIETA' A RESPONSABILITA' LIMITATA (IT) | 2018-01-04 | — | — | WO | disclosed |
| US-7378409-B2 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| EP-1656138-A4 | SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2007-04-18 | — | — | EP | disclosed |
| US-7199105-B2 | Lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS, INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-7164011-B2 | Lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS, INC. (US) | 2007-01-16 | — | — | US | disclosed |
| EP-1656138-A2 | SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2006-05-17 | — | — | EP | disclosed |
| EP-1529052-A2 | LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2005-05-11 | — | — | EP | disclosed |
| WO-2005020899-A2 | SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
| US-20040230046-A1 | Lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. | 2004-11-18 | — | — | US | disclosed |
| US-4163021-A | Synthesis of 2,6,10-trimethyl-undecan-1-ol | HOFFMANN-LA ROCHE INC. (US) | 1979-07-31 | — | — | US | disclosed |
| US-4151205-A | Synthesis of vitamin E | HOFFMAN-LA ROCHE INC. (US) | 1979-04-24 | — | — | US | disclosed |
| US-4140702-A | Process for producing vitamin E intermediate compounds | HOFFMANN-LA ROCHE INC. (US) | 1979-02-20 | — | — | US | disclosed |
| US-4140723-A | Intermediate compounds for producing vitamin E | HOFFMANN-LA ROCHE INC. (US) | 1979-02-20 | — | — | US | disclosed |
| US-4118373-A | Preparation of urethane elastomers from epoxy resin, polyols and polyisocyanates using a catalyst composition of an organometal salt with either nitrogen or phosphorus compounds | THE DOW CHEMICAL COMPANY (US) | 1978-10-03 | — | — | US | disclosed |
| US-4111961-A | Silicon ester of carboxylic acid | HOFFMANN-LA ROCHE INC. (US) | 1978-09-05 | — | — | US | disclosed |
| US-4107183-A | Synthesis of optically active carboxylic acid esters | HOFFMANN-LA ROCHE INC. (US) | 1978-08-15 | — | — | US | disclosed |
| US-4081491-A | HEAT CURABLE | SHELL OIL COMPANY (US) | 1978-03-28 | — | — | US | disclosed |
| US-4051153-A | Intermediates in the synthesis of vitamin E | HOFFMANN-LA ROCHE INC. (US) | 1977-09-27 | — | — | US | disclosed |
| US-4041058-A | Synthesis of 2,6,10-trimethyl-undecan-1-ol | HOFFMANN-LA ROCHE INC. (US) | 1977-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040230046-A1 | Lincomycin derivatives possessing antibacterial activity | NRDC, NISCH, CLSPN | HIF1A 4458/4885ALDH1A1 2737/4885TSHR 3561/4885 |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | HIF1A 4282/4885ALDH1A1 827/4885TSHR 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.